ᅟ
Background
Methods
Patients
Tumor tissue and plasma sample collection and mutational analysis
Statistical analysis
Results
Study design and patient characteristics
Variables | No. of patients (%) |
---|---|
Gender | |
Male | 23(33.3) |
Female | 46(66.7) |
Age | |
≤ 40 | 5 (7.2) |
> 40 | 64(92.8) |
ECOG performance status | |
0–1 | 58(84.1) |
2 | 11(15.9) |
Histologic subtype | |
Adenocarcinoma | 67(97.1) |
Adenosquamous carcinoma | 2 (2.9) |
Smoking status | |
Smoker | 22(31.9) |
Non-smoker | 47(68.1) |
TNM Stage | |
IIIB | 20(29.0) |
IVA | 21(30.4) |
IVB | 28(40.6) |
M Stage | |
M1a | 19(38.8) |
M1b | 4 (8.2) |
M1c | 26(53.0) |
First generation EGFR TKIs | |
Gefitinib | 22(31.8) |
Elortinib | 15(21.7) |
Ecotinib | 31(44.9) |
Two or more TKI drugs | 1 (1.4) |
EGFR mutation detection | |
FFPE slieds by cobas | 22 |
cfDNA by cobas | 47 |
T790 M ddPCR assay | 69 |
Total | 69 |
Detection of T790M mutation by cobas® and ddPCR platform
EGFR T790M detected by any method | EGFR T790M detected by plama ctDNA ddPCR | T790M detected by cobas plama ctDNA test | Cobas Activating Mutation SQI | Cobas T790M SQI | ddPCR T790M quantitative | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Total | Mutant | Wild type |
P
| Mutant | Wild type |
P
| Mutant | Wild type |
P
| Mean |
P
| Mean |
P
| Mean |
P
|
Gender | ||||||||||||||||
Male | 23 | 12 | 11 | 1 | 11 | 12 | 0.864 | 2 | 12 | 0.7 | 10.24 | 0.859 | 9.81 | 0.101 | 0.52 | 0.307 |
Female | 46 | 24 | 22 | 21 | 25 | 8 | 25 | 10.55 | 8.17 | 1.4 | ||||||
Smoking status | ||||||||||||||||
Smoker | 22 | 11 | 11 | 0.805 | 10 | 12 | 0.916 | 3 | 11 | 1 | 10.59 | 0.897 | 9.8 | 0.472 | 1.63 | 0.384 |
Non-smoker | 47 | 25 | 22 | 22 | 25 | 7 | 26 | 10.37 | 7.94 | 0.86 | ||||||
Clinical Stage | ||||||||||||||||
IIIB | 20 | 9 | 11 | 0.495 | 6 | 14 | 0.176 | 2 | 12 |
0.003
| 9.24 | 0.444 | 7.8 | 0.77 | 0.29 |
0.033
|
IVA | 21 | 10 | 11 | 10 | 11 | 0 | 15 | 10.03 | NA | 0.2 | ||||||
IVB | 28 | 17 | 11 | 16 | 12 | 8 | 10 | 11.51 | 8.68 | 2.37 | ||||||
M Stage | ||||||||||||||||
M1a | 19 | 9 | 10 | 0.627 | 9 | 10 | 0.827 | 0 | 15 |
0.004
| 10.03 | 0.541 | NA | NA | 0.21 | 0.178 |
M1b | 4 | 2 | 2 | 2 | 2 | 0 | 1 | NA | NA | 1.07 | ||||||
M1c | 26 | 16 | 10 | 15 | 11 | 8 | 9 | 11.51 | 8.5 | 2.4 | ||||||
Time of EGFR-TKI treatment | ||||||||||||||||
≤ 6 months | 14 | 6 | 8 | 0.733 | 6 | 8 | 0.952 | 1 | 6 | 0.621 | 10.5 | 0.082 | 8.99 | 0.203 | 0.83 | 0.472 |
6–12 months | 26 | 14 | 12 | 12 | 14 | 5 | 12 | 12.71 | 10.32 | 1.75 | ||||||
>12 months | 29 | 16 | 13 | 14 | 15 | 4 | 19 | 8.86 | 6.11 | 0.67 |